Head-to-head evidence
FT819 vs UTAA09
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Systemic Lupus Erythematosus
Shared mechanism: CD19 · full Systemic Lupus Erythematosus pipeline
FT819
Developed by Fate Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: September 2027 · NCT06308978 (registry estimate)
UTAA09
Developed by PersonGen BioTherapeutics (Suzhou) Co., Ltd.
NCT06417398 · Phase 1 · status unknown
This is an open-label, single-arm study with no control group and only 10 patients, and it has not yet reported any results, so there is no controlled evidence here yet.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: FT819's landscape · UTAA09's landscape